REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – The following is a summary of real-world studies of current DMT use in clinical practice. Read More
Latest News
Daclizumab: DECIDE trial update
October 8, 2015REPORT FROM ECTRIMS – BARCELONA, SPAIN – OCTOBER 7-10, 2015 – DECIDE is the second phase III trial evaluating daclizumab, an anti-CD25 monoclonal antibody that modulates IL-2 signalling. Primary results were presented at the American Academy of Neurology annual meeting (Kappos et al. AAN 2015; abstract S4.003) but are not yet published. Subjects (mean age 36 years) were randomized to subcutaneous daclizumab 150 mg q4weeks or intramuscular interferon-beta-1a for 96-144 weeks.
The annualized relapse rate (ARR) was significantly lower with daclizumab versus IFNbeta (0.216 vs. 0.393). The risk of three-month confirmed disability progression was reduced 16% with daclizumab versus active control but did not achieve statistical significance. Read More
Sublingual apomorphine in PD: phase II results
September 2, 2015Report from the 1st Congress of the European Academy of Neurology, Berlin, Germany, June 20-23, 2015 – Subcutaneous apomorphine is clinically available in many countries for the acute treatment of Off periods in PD. Alternative delivery methods have been investigated for several decades.
A new sublingual formulation, APL-130277, by a Canadian drugmaker has now completed early open-label phase IIa testing and results are available (Hauser et al. EAN 2015; abstract P2153). Read More
Evaluating neurodegeneration biomarkers in AD
September 2, 2015Report from the 1st Congress of the European Academy of Neurology, Berlin, Germany, June 20-23, 2015 – Imaging and CSF biomarkers of neurodegeneration appear to be correlated only in patients with Alzheimer’s disease with beta-amyloid pathology, according to a study by the Alzheimer’s Disease Neuroimaging Initiative (Andriutal et al. EAN 2015;O3102). Read More